Assignee
CORVUS PHARMACEUTICALS INC
US·15 granted patents·11 pending applications·22 citations·filing 2016–2024
Top patents by PatentIndex Score
26 records- 0194US10822426B2Humanized anti-CD73 antibodiesCORVUS PHARMACEUTICALS INC·Filed 2016·Granted Nov 3, 2020·11 cites·27 claims
- 0283US10912776B2Methods of treating cancerCORVUS PHARMACEUTICALS INC·Filed 2016·Granted Feb 9, 2021·3 cites·12 claims
- 0381US2024383884A1Compounds and methods for modulating interleukin-2-inducible t-cell kinaseCORVUS PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0479US11008314B2Compounds and methods for modulating interleukin-2-inducible t-cell kinaseCORVUS PHARMACEUTICALS INC·Filed 2017·Granted May 18, 2021·1 cites·30 claims
- 0578US11266649B2Pharmaceutical formulationsCORVUS PHARMACEUTICALS INC·Filed 2019·Granted Mar 8, 2022·2 cites·16 claims
- 0678US10870652B2Compounds and methods for modulating bruton's tyrosine kinaseCORVUS PHARMACEUTICALS INC·Filed 2017·Granted Dec 22, 2020·2 cites·28 claims
- 0777US10793636B2Anti-CD73 antibodiesCORVUS PHARMACEUTICALS INC·Filed 2017·Granted Oct 6, 2020·1 cites·10 claims
- 0876US11040040B2Methods of treating cancerCORVUS PHARMACEUTICALS INC·Filed 2018·Granted Jun 22, 2021·2 cites·15 claims
- 0971US11897874B2Compounds and methods for modulating Interleukin-2-inducible T-cell kinaseCORVUS PHARMACEUTICALS INC·Filed 2021·Granted Feb 13, 2024·0 cites·29 claims
- 1065US12351644B2Anti-CD73 antibodiesCORVUS PHARMACEUTICALS INC·Filed 2020·Granted Jul 8, 2025·0 cites·11 claims
- 1164US12023337B2Methods of treating cancerCORVUS PHARMACEUTICALS INC·Filed 2020·Granted Jul 2, 2024·0 cites·22 claims
- 1263US12174192B2Methods for detecting and treating cancers having adenosine pathway activationCORVUS PHARMACEUTICALS INC·Filed 2019·Granted Dec 24, 2024·0 cites·11 claims
- 1362US11859007B2Humanized anti-CD73 antibodiesCORVUS PHARMACEUTICALS INC·Filed 2020·Granted Jan 2, 2024·0 cites·15 claims
- 1460US12116635B2Methods for detecting and treating cancers having adenosine pathway activationCORVUS PHARMACEUTICALS INC·Filed 2019·Granted Oct 15, 2024·0 cites·19 claims
- 1560US2024301082A1Anti-cd73 compounds to treat oncovirus-positive cancersCORVUS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1658US2025213587A1Itk inhibitors for increasing th1 cell activityCORVUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1752US2024218073A1Immunomodulatory anti-cd73 antibodies and uses thereofCORVUS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1851US2022242963A1B-cell activating cd73 antibodiesCORVUS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1948US2020261462A1Combination therapy for cancer treatmentCORVUS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2045US2021008206A1Adenosine pathway inhibitors for cancer treatmentCORVUS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2142US2021107989A1Methods for treating cd73hi tumorsCORVUS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2242US2019022096A1Methods of treating cancerCORVUS PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2341US2020079793A1Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptorCORVUS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2440US2019231783A1Pharmaceutical formulationsCORVUS PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2537US11254686B1Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptorCORVUS PHARMACEUTICALS INC·Filed 2018·Granted Feb 22, 2022·0 cites·15 claims
- 2636US10654825B2Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereofCORVUS PHARMACEUTICALS INC·Filed 2018·Granted May 19, 2020·0 cites·57 claims
Join the waitlist — get patent alerts
Get an alert when CORVUS PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →